• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中西部肉瘤试验合作组织:以协作方式连接学术与社区网络以应对肉瘤。

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma.

作者信息

Heater Natalie K, Okuno Scott, Robinson Steven, Attia Steven, Seetharam Mahesh, Siontis Brittany L, Yoon Janet, Chawla Sant, Milhem Mohammed M, Monga Varun, Skubitz Keith, Charlson John, Hirbe Angela C, Weiss Mia C, Van Tine Brian, Agulnik Mark

机构信息

Department of Medicine, Northwestern University, Chicago, IL 60611, USA.

Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

J Clin Med. 2023 Mar 29;12(7):2561. doi: 10.3390/jcm12072561.

DOI:10.3390/jcm12072561
PMID:37048645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10095464/
Abstract

The treatment of sarcoma necessitates a collaborative approach, given its rarity and complex management. At a single institution, multidisciplinary teams of specialists determine and execute treatment plans involving surgical, radiation, and medical management. Treatment guidelines for systemic therapies in advanced or nonresectable soft tissue sarcoma have advanced in recent years as new immunotherapies and targeted therapies become available. Collaboration between institutions is necessary to facilitate accrual to clinical trials. Here, we describe the success of the Midwest Sarcoma Trials Partnership (MWSTP) in creating a network encompassing large academic centers and local community sites. We propose a new model utilizing online platforms to expand the reach of clinical expertise for the treatment of advanced soft tissue sarcoma.

摘要

鉴于肉瘤的罕见性和复杂的管理方式,其治疗需要采用协作方法。在单一机构中,多学科专家团队确定并执行涉及手术、放疗和药物管理的治疗计划。近年来,随着新的免疫疗法和靶向疗法的出现,晚期或不可切除软组织肉瘤的全身治疗指南也在不断发展。机构间的合作对于促进临床试验的入组是必要的。在此,我们描述了中西部肉瘤试验合作组织(MWSTP)在创建一个涵盖大型学术中心和当地社区机构的网络方面所取得的成功。我们提出了一种利用在线平台的新模式,以扩大治疗晚期软组织肉瘤临床专业知识的覆盖范围。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6130/10095464/0aec63556dee/jcm-12-02561-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6130/10095464/dbc387bf4bc3/jcm-12-02561-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6130/10095464/0aec63556dee/jcm-12-02561-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6130/10095464/dbc387bf4bc3/jcm-12-02561-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6130/10095464/0aec63556dee/jcm-12-02561-g002.jpg

相似文献

1
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma.中西部肉瘤试验合作组织:以协作方式连接学术与社区网络以应对肉瘤。
J Clin Med. 2023 Mar 29;12(7):2561. doi: 10.3390/jcm12072561.
2
The NCI All Ireland Cancer Conference.美国国家癌症研究所全爱尔兰癌症会议。
Oncologist. 1999;4(4):275-277.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework.骨肉瘤和软组织肉瘤的多学科管理:一个基本的组织框架。
J Multidiscip Healthc. 2015 Feb 19;8:109-15. doi: 10.2147/JMDH.S49805. eCollection 2015.
5
Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?应用近距离放射治疗和外部束放射治疗的算法方法是否能为肢体软组织肉瘤患者带来良好的功能、局部控制率和低发病率?
Clin Orthop Relat Res. 2018 Mar;476(3):634-644. doi: 10.1007/s11999.0000000000000079.
6
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.帕博利珠单抗治疗晚期软组织肉瘤和骨肉瘤(SARC028):一项多中心、双队列、单臂、开放标签的2期试验。
Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4.
7
Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.组织学特异性治疗晚期软组织肉瘤和良性结缔组织肿瘤。
Curr Treat Options Oncol. 2012 Sep;13(3):285-98. doi: 10.1007/s11864-012-0194-4.
8
Accreditation for centers of sarcoma surgery.肉瘤手术中心认证。
Updates Surg. 2017 Mar;69(1):1-7. doi: 10.1007/s13304-016-0382-z. Epub 2016 Aug 8.
9
Does Advanced Imaging Have a Role in Detecting Local Recurrence of Soft-tissue Sarcoma?高级影像学在检测软组织肉瘤局部复发中的作用如何?
Clin Orthop Relat Res. 2020 Dec;478(12):2812-2820. doi: 10.1097/CORR.0000000000001351.
10
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.日本作为超老龄化社会的领跑者:来自日本医学与医疗护理的视角
Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5.

引用本文的文献

1
Prices and Trends in FDA-Approved Medications for Sarcomas.美国食品药品监督管理局(FDA)批准的肉瘤治疗药物的价格与趋势
Cancers (Basel). 2024 Apr 18;16(8):1545. doi: 10.3390/cancers16081545.
2
On the Virtues of "Team Medicine"-A City of Hope Perspective.论“团队医疗”的优点——希望之城视角
J Clin Med. 2023 Jul 26;12(15):4897. doi: 10.3390/jcm12154897.

本文引用的文献

1
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.TSC-1 和 -2 突变对恶性 PEComa 治疗反应的影响:一项多中心回顾性分析。
Genes (Basel). 2022 Oct 24;13(11):1932. doi: 10.3390/genes13111932.
2
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.软组织肉瘤,第 2.2022 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Jul;20(7):815-833. doi: 10.6004/jnccn.2022.0035.
3
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.
妊娠期间使用蒽环类药物和/或异环磷酰胺治疗肉瘤的妊娠结局。
Cancer Med. 2022 Sep;11(18):3471-3478. doi: 10.1002/cam4.4707. Epub 2022 Mar 28.
4
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
5
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.FDA 批准概要:替沃扎尼治疗复发或难治性肾细胞癌。
Clin Cancer Res. 2022 Feb 1;28(3):441-445. doi: 10.1158/1078-0432.CCR-21-2334. Epub 2021 Aug 20.
6
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.一项关于regorafenib 治疗血管肉瘤的开放标签单臂 2 期研究。
Eur J Cancer. 2021 Sep;154:201-208. doi: 10.1016/j.ejca.2021.06.027. Epub 2021 Jul 17.
7
Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.让“冷”肿瘤变“热”:肉瘤的免疫疗法
Ann Transl Med. 2021 Jun;9(12):1039. doi: 10.21037/atm-20-6041.
8
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.免疫检查点抑制剂在软组织肉瘤治疗中的应用:系统评价和荟萃分析。
Eur J Cancer. 2021 Jul;152:165-182. doi: 10.1016/j.ejca.2021.04.034. Epub 2021 Jun 6.
9
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.帕唑帕尼联合口服拓扑替康治疗转移性和不可切除的软组织和骨肉瘤患者的 II 期研究。
Br J Cancer. 2021 Aug;125(4):528-533. doi: 10.1038/s41416-021-01448-0. Epub 2021 May 28.
10
Impact of a Virtual Multidisciplinary Sarcoma Case Conference on Treatment Plan and Survival in a Large Integrated Healthcare System.虚拟多学科肉瘤病例讨论会对大型综合医疗系统中治疗方案及生存情况的影响
JCO Oncol Pract. 2021 Nov;17(11):e1711-e1718. doi: 10.1200/OP.20.01078. Epub 2021 Apr 14.